IL295938A - Therapeutic uses of macrocyclic compounds - Google Patents

Therapeutic uses of macrocyclic compounds

Info

Publication number
IL295938A
IL295938A IL295938A IL29593822A IL295938A IL 295938 A IL295938 A IL 295938A IL 295938 A IL295938 A IL 295938A IL 29593822 A IL29593822 A IL 29593822A IL 295938 A IL295938 A IL 295938A
Authority
IL
Israel
Prior art keywords
cancer
carcinoma
met
compound
alkyl
Prior art date
Application number
IL295938A
Other languages
English (en)
Hebrew (he)
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of IL295938A publication Critical patent/IL295938A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL295938A 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds IL295938A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062984159P 2020-03-02 2020-03-02
PCT/US2021/020255 WO2021178296A1 (en) 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds

Publications (1)

Publication Number Publication Date
IL295938A true IL295938A (en) 2022-10-01

Family

ID=77613771

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295938A IL295938A (en) 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds

Country Status (11)

Country Link
US (1) US20250262216A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114530A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023515687A (cg-RX-API-DMAC7.html)
KR (1) KR20230022151A (cg-RX-API-DMAC7.html)
CN (1) CN115397514A (cg-RX-API-DMAC7.html)
AU (1) AU2021229457A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017425A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174455A1 (cg-RX-API-DMAC7.html)
IL (1) IL295938A (cg-RX-API-DMAC7.html)
MX (1) MX2022010945A (cg-RX-API-DMAC7.html)
WO (1) WO2021178296A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902417B (zh) 2018-04-25 2023-07-28 北京普祺医药科技股份有限公司 一种二芳基巨环化合物、药物组合物以及其用途
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
BR112018000297A2 (pt) * 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
AU2017302019A1 (en) * 2016-07-28 2019-02-07 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
WO2021063276A1 (zh) * 2019-09-30 2021-04-08 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
EP4114530A1 (en) 2023-01-11
WO2021178296A1 (en) 2021-09-10
JP2023515687A (ja) 2023-04-13
AU2021229457A1 (en) 2022-10-20
CA3174455A1 (en) 2021-09-10
US20250262216A1 (en) 2025-08-21
KR20230022151A (ko) 2023-02-14
BR112022017425A2 (pt) 2022-11-29
EP4114530A4 (en) 2024-04-17
MX2022010945A (es) 2022-10-07
CN115397514A (zh) 2022-11-25

Similar Documents

Publication Publication Date Title
US20250375451A1 (en) Chiral diaryl macrocycles and uses thereof
IL267992B2 (en) Combination therapy involving macrocyclic diaryl compounds
US20130004481A1 (en) Anticancer therapy
CN116916914A (zh) Sos1抑制剂及其用途
EP3585389A1 (en) Treatment of egfr-driven cancer with fewer side effects
US8937095B2 (en) Anticancer compounds
IL311387A (en) Methods for solid tumor treatment using macrocyclic heteroaromatic ether compounds
WO2019165473A1 (en) Methods of treatment of cancer comprising cdc7 inhibitors
IL278596B2 (en) RAS oncoprotein inhibitors, methods for preparing and methods for using them
AU2021229457A1 (en) Therapeutic uses of macrocyclic compounds
CA3245914A1 (en) METHODS OF TREATMENT OF A SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAE-22-AMINE
WO2026015740A1 (en) Macrocyclic ras inhibitors
HK40097088A (en) Indole derivatives as ras inhibitors in the treatment of cancer
BR112024002063B1 (pt) Compostos que inibem isoforma alfa de pi3k, composições que o compreendem, usos dos mesmos, e combinações
HK40076319A (en) Ras inhibitors